Radioligand therapy and imaging

Radioligand therapy and imaging

LOCAMETZ®

Kit for the preparation of gallium Ga 68 gozetotide injection

SmPC

Denmark

• Summary of product characteristics (PDF 0.4 MB)

Estonia

• Summary of product characteristics (PDF 0.4 MB)

Finland

• Summary of product characteristics (PDF 0.4 MB)

France

• Locametz transparency notice (PDF 0.7 MB)
• Summary of product characteristics - Locametz (PDF 0.5 MB)

Iceland

• Summary of product characteristics (PDF 0.4 MB)

Latvia

• Summary of product characteristics (PDF 0.4 MB)

Lithuania

• Summary of product characteristics (PDF 0.4 MB)

Norway

• Summary of product characteristics (PDF 0.4 MB)

Poland

• Summary of product characteristics (PDF 0.4 MB)
• Patient information leaflet (PDF 0.2 MB)

Slovakia

• Summary of product characteristics (PDF 0.4 MB)

Sweden

• Summary of product characteristics (PDF 0.4 MB)

 

---

LUTATHERA®

Our brand names for lutetium Lu 177 dotatate / lutetium (177Lu) oxodotreotide

SmPC

 

Denmark

• Summary of product characteristics (PDF 1.5 MB)

Estonia

• Summary of product characteristics (PDF 1.4 MB)

Finland

• Summary of product characteristics (PDF 1.3 MB)

France

• Transparency notice (PDF 0.5 MB)
• Summary of product characteristics (PDF 1.4 MB)

Iceland

• Summary of product characteristics (PDF 1.3 MB)

Latvia

• Summary of product characteristics (PDF 1.4 MB)

Lithuania

• Summary of product characteristics (PDF 1.4 MB)

Norway

• Summary of product characteristics (PDF 1.3 MB)

Poland

• Summary of product characteristics (PDF 1.4 MB)

Slovakia

• Summary of product characteristics (PDF 1.8 MB)

Sweden

• Summary of product characteristics (PDF 1.3 MB)

 

---

LysaKare®

LysaKare® 25g/25g solution for reduction of renal (kidney) radiation exposure during peptide-receptor radionuclide therapy with Lutathera®

SmPC

Denmark

• Summary of product characteristics (PDF 0.3 MB)

Estonia

• Summary of product characteristics (PDF 0.3 MB)

Finland

• Summary of product characteristics (PDF 0.3 MB)

France

• Transparency notice (PDF 0.5 MB)
• Summary of product characteristics (PDF 0.3 MB)

Iceland

• Summary of product characteristics (PDF 0.3 MB)

Latvia

• Summary of product characteristics (PDF 0.3 MB)

Lithuania

• Summary of product characteristics (PDF 0.3 MB)

Norway

• Summary of product characteristics (PDF 0.3 MB)

Poland

• Summary of product characteristics (PDF 0.3 MB)

Slovakia

• Summary of product characteristics (PDF 0.3 MB)

Sweden

• Summary of product characteristics (PDF 0.3 MB)

 

---

PLUVICTO®

Our brand name for lutetium Lu 177 vipivotide tetraxetan

SmPC

Denmark

• Summary of product characteristics (PDF 0.6 MB)

Estonia

• Summary of product characteristics (PDF 0.6 MB)

Finland

• Summary of product characteristics (PDF 0.6 MB)

France

• Pluvicto transparency notice (PDF 0.7 MB)
• Summary of product characteristics - Pluvicto (PDF 0.8 MB)

Iceland

• Summary of product characteristics (PDF 0.6 MB)

Latvia

• Summary of product characteristics (PDF 0.6 MB)

Lithuania

• Summary of product characteristics (PDF 0.6 MB)

Norway

• Summary of product characteristics (PDF 0.6 MB)

Poland

• Summary of product characteristics (PDF 0.5 MB)
• Patient information leaflet (PDF 0.3 MB)

Slovakia

• Summary of product characteristics (PDF 0.7 MB)

Sweden

• Summary of product characteristics (PDF 0.6 MB)

 

---

SOMAKIT TOC®

Kit for the preparation of gallium (Ga 68) edotreotide solution

SmPC

Denmark

• Summary of product characteristics (PDF 0.6 MB)

Estonia

• Summary of product characteristics (PDF 0.5 MB)

Finland

• Summary of product characteristics (PDF 0.5 MB)

France

• Transparency notice (PDF 0.4 MB)
• Summary of product characteristics (PDF 0.6 MB)

Iceland

• Summary of product characteristics (PDF 0.5 MB)

Latvia

• Summary of product characteristics (PDF 0.6 MB)

Lithuania

• Summary of product characteristics (PDF 0.5 MB)

Norway

• Summary of product characteristics (PDF 0.6 MB)

Poland

• Summary of product characteristics (PDF 0.6 MB)

Slovakia

• Summary of product characteristics (PDF 0.6 MB)

Sweden

• Summary of product characteristics (PDF 0.5 MB)

 

1. https://prod1.adacap.com/our-products/radioligand-therapy-and-imaging
2. https://prod1.adacap.com/sites/novartis_adacap/files/da-locametz-inn-gozetotide.pdf
3. https://prod1.adacap.com/sites/novartis_adacap/files/et-locametz-inn-gozetotide.pdf
4. https://prod1.adacap.com/sites/novartis_adacap/files/fi-locametz-inn-gozetotide.pdf
5. https://prod1.adacap.com/sites/novartis_adacap/files/Avis-Transparence-Locametz.pdf
6. https://prod1.adacap.com/sites/novartis_adacap/files/CP_NPI_Locametz_25microgram_null_02-Oct-23_French.pdf
7. https://prod1.adacap.com/sites/novartis_adacap/files/is-locametz-inn-gozetotide.pdf
8. https://prod1.adacap.com/sites/novartis_adacap/files/lv-locametz-inn-gozetotide.pdf
9. https://prod1.adacap.com/sites/novartis_adacap/files/lt-locametz-inn-gozetotide.pdf
10. https://prod1.adacap.com/sites/novartis_adacap/files/no-locametz-inn-gozetotide.pdf
11. https://prod1.adacap.com/sites/novartis_adacap/files/Locametz_ChPL.pdf
12. https://prod1.adacap.com/sites/novartis_adacap/files/Locametz_Ul.pdf
13. https://prod1.adacap.com/sites/novartis_adacap/files/sk-locametz-inn-gozetotide.pdf
14. https://prod1.adacap.com/sites/novartis_adacap/files/sv-locametz-inn-gozetotide.pdf
15. https://prod1.adacap.com/sites/novartis_adacap/files/da-lutathera-inn-lutetium-177lu-oxodotreotide.pdf
16. https://prod1.adacap.com/sites/novartis_adacap/files/et-lutathera-inn-lutetium-177lu-oxodotreotide.pdf
17. https://prod1.adacap.com/sites/novartis_adacap/files/fi-lutathera-inn-lutetium-177lu-oxodotreotide.pdf
18. https://prod1.adacap.com/sites/novartis_adacap/files/CT-16606_LUTATHERA_PIC_INS_Avis3_CT16606.pdf
19. https://prod1.adacap.com/sites/novartis_adacap/files/fr-lutathera-inn-lutetium-177lu-oxodotreotide.pdf
20. https://prod1.adacap.com/sites/novartis_adacap/files/is-lutathera-inn-lutetium-177lu-oxodotreotide.pdf
21. https://prod1.adacap.com/sites/novartis_adacap/files/lv-lutathera-inn-lutetium-177lu-oxodotreotide.pdf
22. https://prod1.adacap.com/sites/novartis_adacap/files/lt-lutathera-inn-lutetium-177lu-oxodotreotide.pdf
23. https://prod1.adacap.com/sites/novartis_adacap/files/no-lutathera-inn-lutetium-177lu-oxodotreotide.pdf
24. https://prod1.adacap.com/sites/novartis_adacap/files/pl-lutathera-inn-lutetium-177lu-oxodotreotide.pdf
25. https://prod1.adacap.com/sites/novartis_adacap/files/sk-lutathera-inn-lutetium-177lu-oxodotreotide.pdf
26. https://prod1.adacap.com/sites/novartis_adacap/files/sv-lutathera-inn-lutetium-177lu-oxodotreotide.pdf
27. https://prod1.adacap.com/sites/novartis_adacap/files/ema-combined-h-4541-da-2.pdf
28. https://prod1.adacap.com/sites/novartis_adacap/files/ema-combined-h-4541-et-2.pdf
29. https://prod1.adacap.com/sites/novartis_adacap/files/ema-combined-h-4541-fi-2.pdf
30. https://prod1.adacap.com/sites/novartis_adacap/files/CT-18132_LYSAKARE_PIC_INS_AvisDef_CT18132.pdf
31. https://prod1.adacap.com/sites/novartis_adacap/files/ema-combined-h-4541-fr-6-v2.pdf
32. https://prod1.adacap.com/sites/novartis_adacap/files/ema-combined-h-4541-is-2.pdf
33. https://prod1.adacap.com/sites/novartis_adacap/files/ema-combined-h-4541-lv-2.pdf
34. https://prod1.adacap.com/sites/novartis_adacap/files/ema-combined-h-4541-lt-2.pdf
35. https://prod1.adacap.com/sites/novartis_adacap/files/ema-combined-h-4541-no-2.pdf
36. https://prod1.adacap.com/sites/novartis_adacap/files/ema-combined-h-4541-pl-2.pdf
37. https://prod1.adacap.com/sites/novartis_adacap/files/ema-combined-h-4541-sk-2.pdf
38. https://prod1.adacap.com/sites/novartis_adacap/files/ema-combined-h-4541-sv-2.pdf
39. https://prod1.adacap.com/sites/novartis_adacap/files/da-pluvicto-inn-lutetium-177lu-vipivotide-tetraxetan.pdf
40. https://prod1.adacap.com/sites/novartis_adacap/files/et-pluvicto-inn-lutetium-177lu-vipivotide-tetraxetan.pdf
41. https://prod1.adacap.com/sites/novartis_adacap/files/fi-pluvicto-inn-lutetium-177lu-vipivotide-tetraxetan.pdf
42. https://prod1.adacap.com/sites/novartis_adacap/files/Avis-Transparence-Pluvicto.pdf
43. https://prod1.adacap.com/sites/novartis_adacap/files/CP_NPI_Pluvicto_1000MBq-mL_Soln_InjInf_18-Oct-23_French.pdf
44. https://prod1.adacap.com/sites/novartis_adacap/files/is-pluvicto-inn-lutetium-177lu-vipivotide-tetraxetan.pdf
45. https://prod1.adacap.com/sites/novartis_adacap/files/lv-pluvicto-inn-lutetium-177lu-vipivotide-tetraxetan.pdf
46. https://prod1.adacap.com/sites/novartis_adacap/files/lt-pluvicto-inn-lutetium-177lu-vipivotide-tetraxetan.pdf
47. https://prod1.adacap.com/sites/novartis_adacap/files/no-pluvicto-inn-lutetium-177lu-vipivotide-tetraxetan.pdf
48. https://prod1.adacap.com/sites/novartis_adacap/files/Pluvicto_ChPL.pdf
49. https://prod1.adacap.com/sites/novartis_adacap/files/Pluvicto_Ul.pdf
50. https://prod1.adacap.com/sites/novartis_adacap/files/sk-pluvicto-inn-lutetium-177lu-vipivotide-tetraxetan.pdf
51. https://prod1.adacap.com/sites/novartis_adacap/files/sv-pluvicto-inn-lutetium-177lu-vipivotide-tetraxetan.pdf
52. https://prod1.adacap.com/sites/novartis_adacap/files/somakit-toc-inn-edotreotide-da.pdf
53. https://prod1.adacap.com/sites/novartis_adacap/files/somakit-toc-inn-edotreotide-et.pdf
54. https://prod1.adacap.com/sites/novartis_adacap/files/somakit-toc-inn-edotreotide-fi.pdf
55. https://prod1.adacap.com/sites/novartis_adacap/files/CT-16063_SOMAKIT_TOC_PIC_INS_Avis1_CT16063-1.pdf
56. https://prod1.adacap.com/sites/novartis_adacap/files/somakit-toc-inn-edotreotide-fr.pdf
57. https://prod1.adacap.com/sites/novartis_adacap/files/somakit-toc-inn-edotreotide-is.pdf
58. https://prod1.adacap.com/sites/novartis_adacap/files/somakit-toc-inn-edotreotide-lv.pdf
59. https://prod1.adacap.com/sites/novartis_adacap/files/somakit-toc-inn-edotreotide-lt.pdf
60. https://prod1.adacap.com/sites/novartis_adacap/files/somakit-toc-inn-edotreotide-no.pdf
61. https://prod1.adacap.com/sites/novartis_adacap/files/somakit-toc-inn-edotreotide-pl.pdf
62. https://prod1.adacap.com/sites/novartis_adacap/files/somakit-toc-inn-edotreotide-sk.pdf
63. https://prod1.adacap.com/sites/novartis_adacap/files/somakit-toc-inn-edotreotide-sv.pdf